Esophageal cancer
Conditions
Interventions
Paclitaxel 50mg/m2 and carboplatin AUC=2 on days 1, 8, 15, 22, 29 and 36.
A total of 50.4 Gy will be given in 28 fractions of 1.8Gy, 5 fractions per week, starting on the first day of chemotherapy.
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: 1. T4N0-1M0; 2. tumour length <10 cm; 3. upper tumour border 2 cm of upper esophageal sphincter; 4. tumor mus not extend more than 4 cm into the stomach; 5. WHO 0-2; 6. adequate haematological, renal, hepatic and pulmonal function, adequate caloric- and/or fluid intake.
Exclusion criteria
Exclusion criteria: 1. Previous chemotherapy and or radiotherapy on mediastinum or upper abdomen; 2. MI within last 6 months; 3. ventricular arrhythmia or congestive heart failure; 4. second or third degree heart blocks; 5. pre-existing neurotoxicity grade >1; 6. active infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine clinically complete biopsy proved response rate after a chemotherapy regime for patients with locally irresectable carcinoma of the esophagus or gatric junction without distant metastases (stage T4N0-1MO). To evaluate toxicity of this chemotherapy regimen in this group of patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine time to progression (TTP) of the disease after treatment. To determine quality of life before, during and after treatment. To obtain insight in survival after treatment. | — |
Contacts
Public ContactA. Gaast, van der
Erasmus Medical Center, Department of Medical Oncology, P.O. Box 2040,
Outcome results
None listed